Neuronetics, Inc. (STIM)
NASDAQ: STIM · Real-Time Price · USD
4.430
+0.040 (0.91%)
At close: Aug 1, 2025, 4:00 PM
4.420
-0.010 (-0.23%)
After-hours: Aug 1, 2025, 6:04 PM EDT
Company Description
Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.
The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics, Inc.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jun 28, 2018 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 716 |
| CEO | Keith Sullivan |
Contact Details
Address: 3222 Phoenixville Pike Malvern, Pennsylvania 19355 United States | |
| Phone | 610 640 4202 |
| Website | neurostar.com |
Stock Details
| Ticker Symbol | STIM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001227636 |
| CUSIP Number | 64131A105 |
| ISIN Number | US64131A1051 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Stephen J. Furlong M.S. | Senior Advisor to the Chief Executive Officer |
| Keith J. Sullivan | President, Chief Executive Officer and Director |
| W. Andrew Macan J.D. | Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| Steven E. Pfanstiel C.M.A., M.B.A. | Chief Financial Officer |
| Cory S. Anderson | SVice President and Chief Technology Officer |
| Lisa Metzner-Rosas | Senior Vice President and Chief Marketing Officer |
| Sara Grubbs | Senior Vice President and Chief Revenue Officer |
| William P. Leonard | Chief Clinic Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 18, 2025 | EFFECT | Notice of Effectiveness |
| Jul 15, 2025 | 8-K | Current Report |
| Jul 3, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 2, 2025 | SD | Form - SD |
| May 28, 2025 | 8-K | Current Report |
| May 13, 2025 | 144 | Filing |
| May 12, 2025 | 144 | Filing |
| May 6, 2025 | 10-Q | Quarterly Report |
| May 6, 2025 | 8-K | Current Report |
| Apr 10, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |